Gainers & Losers Of Mar.6: TGTX, CNCE, DXTR, KURA, ARGS...

TG Therapeutics' phase III trial of TG-1101 in patients with high risk Chronic Lymphocytic Leukemia has met its primary endpoint.

from RTT - Biotech http://ift.tt/2n8dgCN
via IFTTT